NCT02821910 - Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Linagliptin/Metformin Extended Release Compared With Single Tablets | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 20, 2016

Primary Completion Date

October 1, 2016

Study Completion Date

October 31, 2016

Conditions

Healthy

Interventions

DRUG

High dose FDC Empagliflozin/Linagliptin/Metformin XR, fed

High dose Empagliflozin/Linagliptin/Metformin extended release (XR) fixed dose combination (FDC) tablet

DRUG

1 tab Empagliflozin +1 tab Linagliptin +2 tabs Metformin XR

1x Empagliflozin + 1x Linagliptin + 2x Metformin extended release (XR) tablets

DRUG

High dose FDC Empagliflozin/Linagliptin/Metformin XR, fasted

High dose Empagliflozin/Linagliptin/Metformin extended release (XR) fixed dose combination (FDC) tablet

DRUG

1 tab Empagliflozin +1 tab Linagliptin +2 tabs Metformin XR

1x Empagliflozin + 1x Linagliptin + 2x Metformin extended release (XR) tablets

DRUG

Low dose FDC Empagliflozin/Linagliptin/Metformin XR, fed

Low dose Empagliflozin/Linagliptin/Metformin extended release (XR) fixed dose combination (FDC) tablet

DRUG

1 tab Empagliflozin +1 tab Linagliptin +2 tabs Metformin XR

1x Empagliflozin + 1x Linagliptin + 2x Metformin extended release (XR) tablets

Trial Locations (1)

Humanpharmakologisches Zentrum Biberach, Biberach